Author:
Goodsaid Federico M.,Amur Shashi,Aubrecht Jiri,Burczynski Michael E.,Carl Kevin,Catalano Jennifer,Charlab Rosane,Close Sandra,Cornu-Artis Catherine,Essioux Laurent,Fornace Albert J.,Hinman Lois,Hong Huixiao,Hunt Ian,Jacobson-Kram David,Jawaid Ansar,Laurie David,Lesko Lawrence,Li Heng-Hong,Lindpaintner Klaus,Mayne James,Morrow Peter,Papaluca-Amati Marisa,Robison Timothy W.,Roth John,Schuppe-Koistinen Ina,Shi Leming,Spleiss Olivia,Tong Weida,Truter Sharada L.,Vonderscher Jacky,Westelinck Agnes,Zhang Li,Zineh Issam
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Reference52 articles.
1. Lesko, L. J. & Woodcock, J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J. 2, 20–24 (2002).
2. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nature Rev. Drug. Discov. 3, 763–769 (2004).
3. Goodsaid, F. & Frueh, F. W. Implementing the U. S. FDA guidance on pharmacogenomic data submissions. Environ. Mol. Mutagen. 48, 354–358 (2007).
4. Orr, M. S., Goodsaid, F., Amur, S., Rudman, A. & Frueh, F. W. The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program. Clin. Pharmacol. Ther. 81, 294–297 (2007).
5. US Food and Drug Administration, European Medicines Agency. Guiding principles processing joint FDA EMEA voluntary genomic data submissions (VGDSs) within the framework of the confidentiality arrangement. EMA website
[online]
, (2006).
Cited by
80 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献